I. Cassaniti

Engineered dimeric and secretory IgA1 neutralized Omicron variants with higher potency than parental IgG.

This study evaluates a microneedle array patch-based S1 subunit vaccine in mice, showing that four doses induce robust, long-lasting immune responses against multiple SARS-CoV-2 variants.

This study evaluates a tetravalent SARS-CoV-2 S1 subunit vaccine in SIV-infected rhesus macaques, showing robust humoral and cellular immune responses, including cross-reactivity against Omicron.

This study shows that a S1 subunit booster vaccine enhances neutralizing antibodies and cross-reactivity against multiple SARS-CoV-2 variants in aged mice vaccinated with an adenovirus-based vaccine.

This paper develops a novel adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein, showing improved immunogenicity in mice against SARS-CoV-2 variants.

This study tracks SARS-CoV-2 immunity in patients up to 15 months post-infection, showing sustained antibody and memory B/T cell responses but reduced neutralization against variants.

This study tracks SARS-CoV-2 specific B- and T-cell responses in convalescent patients 6-8 months post-infection, finding sustained memory cell responses despite declining antibody levels.